A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms NewLira
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 10 Dec 2018 Planned End Date changed from 1 Oct 2015 to 1 Dec 2018.
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.